These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA. Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793 [TBL] [Abstract][Full Text] [Related]
3. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Hildenbrand R; Schaaf A Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473 [TBL] [Abstract][Full Text] [Related]
4. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer. Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797 [TBL] [Abstract][Full Text] [Related]
5. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori. Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653 [TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas. Fujii T; Obara T; Tanno S; Ura H; Kohgo Y Hepatogastroenterology; 1999; 46(28):2299-308. PubMed ID: 10521987 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer. Spyratos F; Bouchet C; Tozlu S; Labroquere M; Vignaud S; Becette V; Lidereau R; Bieche I Anticancer Res; 2002; 22(5):2997-3003. PubMed ID: 12530032 [TBL] [Abstract][Full Text] [Related]
9. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis. Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903 [TBL] [Abstract][Full Text] [Related]
10. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx]. Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766 [TBL] [Abstract][Full Text] [Related]
11. Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression. Lamy PJ; Verjat T; Servanton AC; Paye M; Leissner P; Mougin B Am J Clin Pathol; 2007 Sep; 128(3):404-13. PubMed ID: 17709314 [TBL] [Abstract][Full Text] [Related]
12. Effect of Tisseel on expression of tissue plasminogen activator and plasminogen activator inhibitor-1. Diamond MP; Kruger M; Saed GM Fertil Steril; 2004 Jun; 81(6):1657-64. PubMed ID: 15193491 [TBL] [Abstract][Full Text] [Related]
13. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ Cancer Res; 2000 Oct; 60(20):5839-47. PubMed ID: 11059781 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307 [TBL] [Abstract][Full Text] [Related]
15. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis. Offersen BV; Pfeiffer P; Andreasen P; Overgaard J Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889 [TBL] [Abstract][Full Text] [Related]
16. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728 [TBL] [Abstract][Full Text] [Related]
17. Effects of glucose and plasminogen activator inhibitor-1 on collagen metabolism in the peritoneum. Higuchi C; Tanihata Y; Nishimura H; Naito T; Sanaka T Ther Apher Dial; 2005 Apr; 9(2):173-81. PubMed ID: 15828931 [TBL] [Abstract][Full Text] [Related]
18. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865 [TBL] [Abstract][Full Text] [Related]
19. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients]. Zhou Q; Liang LJ; Peng BG; Zhen YY Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of RegIV in peritoneal dissemination of gastric cancer and its potential as A novel marker for the detection of peritoneal micrometastasis. Miyagawa K; Sakakura C; Nakashima S; Yoshikawa T; Fukuda K; Kin S; Nakase Y; Shimomura K; Oue N; Yasui W; Hayasizaki H; Okazaki Y; Yamagishi H; Hagiwara A; Otsuji E Anticancer Res; 2008; 28(2B):1169-79. PubMed ID: 18505053 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]